CPG Management of Dyslipidemia

What is the recommended LDL-C target for individuals at very high cardiovascular risk?

• < 2.6 mmol/L

• < 1.8 mmol/L

• < 1.4 mmol/L

• < 2.0 mmol/L

Which of the following statements is TRUE regarding statin therapy?

• Statin therapy can be discontinued if LDL-C targets are achieved within 6 months.

• Statin therapy should only be prescribed for secondary prevention.

• Statin therapy is recommended for individuals with a high cardiovascular risk, even if their LDL-C levels are below 1.8 mmol/L.

• Statin therapy should be initiated in all adults above 50 years regardless of risk.

Which of the following is recommended as the first-line treatment for dyslipidemia in patients with diabetes?

• Fibrates

• Omega-3 fatty acids

• PCSK9 inhibitors

• Statins

Which of the following is considered a secondary cause of dyslipidemia?

• Osteoporosis

• Rheumatoid arthritis

• Hypertension

• Hypothyroidism

What is the primary goal of statin therapy in high cardiovascular risk patients?

• To lower triglyceride levels

• To achieve LDL-C targets

• To increase HDL-C levels

• To manage blood pressure

Which lipid parameter is recommended to assess residual risk after LDL-C goals are achieved?

• Total cholesterol

• HDL-C

• Triglyceride

• Non-HDL-C

What is the recommendation for the use of ezetimibe in dyslipidemia management?

• It is a first-line therapy for all patients with dyslipidemia.

• It is added to statin therapy if LDL-C targets are not achieved with the maximum tolerated dose of statin.

• It should only be used in patients who cannot tolerate statins.

• It is recommended only for patients with familial hypercholesterolemia.

What is the recommended frequency of lipid profile testing for patients who are on stable lipid-lowering therapy?

• Every 3 months

• Every 6-12 months

• Monthly

• Every 2 years

Which patient population is most strongly recommended for screening for familial hypercholesterolemia (FH)?

• Individuals with a family history of premature cardiovascular disease.
• Patient with triglyceride levels > 2.3 mmol/L.

• Patients with HDL-C levels below 1.0 mmol/L

• Individuals under the age of 30

What is the primary therapeutic goal for patients with hypertriglyceridemia (TG > 4.5 mmol/L)?

• Increase HDL-C levels.

• Reduce total cholesterol.

• Lower triglyceride levels to < 2.3 mmol/L.

• To achieve non-HDL-C target.